09/15/2014 - 3:14pm

Dick Tracy has nothing on the wearable gadgets under development to help people better police their diabetes. Wearable technologies in its totality — which include Google Glass and the Apple Watch — are part of a booming market that’s expected to swell to $20 billion by 2015 and is further expected to grow at a compound annual growth rate of nearly 40% over the next six years.

09/15/2014 - 3:14pm

Close to half (40%) of the U.S. adult population — roughly 126 million — is expected to develop Type 2 diabetes at some point during their lifetime, according to a study published in The Lancet Diabetes and Endocrinology in August.

09/09/2014 - 11:54am

AstraZeneca's once-weekly Bydureon (exenatide extended-release for injectable suspension) pen now is available in pharmacies across the United States, the company announced.

09/05/2014 - 10:21am

Univision on Thursday announced the official sponsors for its singing reality competition, “Va Por Ti” (This One’s For You) , a co-production of Televisa and Univision. 

09/03/2014 - 10:56am

To help encourage early detection of diabetes in communities around the United States, Sam’s Club Pharmacy will host free diabetes screenings to both members and non-members on Sept. 13.

08/26/2014 - 11:51am

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Co. announced that Jardiance (empagliflozin) tablets are now available by prescription in pharmacies across the United States.

08/25/2014 - 12:20pm

Nipro Diagnostics announced that the Food and Drug Administration approved its True Metrix self-monitoring blood-glucose system, as well as the True Metrix Pro professional monitoring blood-glucose system.

08/19/2014 - 12:04pm

The Food and Drug Administration has granted tentative approval for Basaglar (insulin glargine injection), which is used to improve glycemic control in adults with Type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with Type 1 diabetes.

08/11/2014 - 11:15am

Sanofi on Monday acquired the rights to Afrezza Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with Type 1 and Type 2 diabetes, from MannKind in a deal that could be worth as much as $925 million.